INSM - Insmed Incorporated
About Insmed Incorporated (https://www.insmed.com)
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| William H. Lewis | President, Chief Executive Officer & Chairman | 1969 | $2,467,420 USD |
| Martina Flammer | Chief Medical Officer | 1964 | $1,216,760 USD |
| Roger Adsett | Chief Operating Officer | 1969 | $1,191,652 USD |
| Michael Alexander Smith | Chief Legal Officer & Corporate Secretary | 1978 | $1,138,096 USD |
| Sara Bonstein | Chief Financial Officer | 1981 | $1,117,676 USD |
| S. Nicole Schaeffer | Chief People Strategy Officer | 1968 | $660,810 USD |
| Brian K. Kaspar | Chief Scientific Officer | 1974 | – |
| Bryan Dunn | Vice President of Investor Relations | – | – |
| Christie Camelio | Chief Compliance Officer | – | – |
| Claire Mulhearn | Vice President of Corporate Communications | – | – |